What's new

INDO-US Trade War : India prepares to battle US pressure on trade laws

Indo-guy

SENIOR MEMBER
Joined
Aug 14, 2013
Messages
4,820
Reaction score
2
Country
India
Location
Singapore
Indian govt prepares to battle US pressure on trade laws - Rediff.com Business


The government held a high-level meeting on Monday to discuss apprehensions that the US government might impose sanctions against Indian companies on the ground of a lax intellectual property rights (IPR) regime.

Delhi, it was decided, would not tolerate such a move from Washington. “It has been decided that India will not cooperate with the US on any sort of investigation on Indian IPR or trade laws,” an official said after Cabinet Secretary Ajit Seth took a meeting of top bureaucrats over the issue.

India, it was decided, might take the US to the World Trade Organization (WTO) if such unwarranted action was taken, while keeping open the door for discussion to allay perceptions on Delhi's trade laws.

The Cabinet secretary reiterated that India was WTO-compliant on Trade Related Intellectual Property Rights, officials said. The government is also compiling cases where the US had breached IPR laws.

Officials attending included the secretaries for foreign affairs, commerce, industrial policy and health. India's ambassador to the US, S Jaishankar, is also discussing the issue with the US government.

The office of the US Trade Representative is expected to issue what is termed a “Special 301” report this month-end or early next month. This is an annual survey in which the USTR is supposed to identify countries which do not provide “adequate and effective” IPR protection or “fair and equitable market access to United States persons that rely upon IPR”.

There is apprehension that the USTR might put India on the Priority Foreign Country list for IPR; this names countries judged to have inadequate intellectual property laws or deny fair and equitable market access to US entities relying on IPR protection.
3350384373314e4e53664d414168502f

Such countries may be subject to sanctions. As a part of such penal action, the US may withdraw benefits under the scheme of Generalised System of Preferences, which provides reduced tariffs for Indian goods entering US markets.

The US International Trade Commission, a quasi-judicial independent federal body which advises the US President, the USTR and the nation’s legislature on trade matters, had begun a probe into India’s trade and industrial policies on February 12.

Since US President Barack Obama’s 2010 India visit, American firms, especially a certain segment of the US pharmaceutical industry, have become extremely vocal about Indian policies on domestic content requirements and IPR.

Policy circles here believe the US is doing these to protect the interest of a handful of pharmaceutical companies, which command influence in policy making circles there. These include Pfizer, Bayer and and Swiss pharma major Novartis.

The department of industrial policy and promotion, under the commerce & industry ministry, has prepared a list of all cases since 1974 where the US is held to have breached IPR laws, rejected patents and invoked compulsory licensing, in sectors ranging from electronics to pharmaceuticals.

During the 2002-2012 period, 20 cases related to pharmaceuticals were invalidated by the US Federal District Courts, compared with 34 related to mechanical devices and 10 to medical devices. Between 2007 and 2011, about 280 cases were identified in the US Federal District Courts where patent validity was determined. Of these, the patent was held valid and enforceable in only 39 cases. In 253 cases, the patent was held invalid.

Refusing to deal with the matter bilaterally, the government has apparently told its American counterpart that such issues should be discussed only at multilateral platforms like the World Intellectual Property Organization and WTO. However, following the Novartis and Bayer-Onyx cases here, the US is concerned that other countries such as Brazil, China and in Africa might follow India’s model of compulsory licensing.

IPR war

* Officials decided India will not cooperate with the US on any sort of investigation on Indian IPR or trade laws

* But it will keep the door open for discussion to allay US perceptions on New Delhi's trade laws

* The government is compiling cases where the US had breached IPR laws

* The office of the US Trade Representative is expected to come out with a report on Special 301 by April-end or early May

* Apprehensions that USTR might put India on the Priority Foreign Country list for IPR, making it subject to sanctions
 
.
Indian govt prepares to battle US pressure on trade laws - Rediff.com Business


The government held a high-level meeting on Monday to discuss apprehensions that the US government might impose sanctions against Indian companies on the ground of a lax intellectual property rights (IPR) regime.

Delhi, it was decided, would not tolerate such a move from Washington. “It has been decided that India will not cooperate with the US on any sort of investigation on Indian IPR or trade laws,” an official said after Cabinet Secretary Ajit Seth took a meeting of top bureaucrats over the issue.

India, it was decided, might take the US to the World Trade Organization (WTO) if such unwarranted action was taken, while keeping open the door for discussion to allay perceptions on Delhi's trade laws.

The Cabinet secretary reiterated that India was WTO-compliant on Trade Related Intellectual Property Rights, officials said. The government is also compiling cases where the US had breached IPR laws.

Officials attending included the secretaries for foreign affairs, commerce, industrial policy and health. India's ambassador to the US, S Jaishankar, is also discussing the issue with the US government.

The office of the US Trade Representative is expected to issue what is termed a “Special 301” report this month-end or early next month. This is an annual survey in which the USTR is supposed to identify countries which do not provide “adequate and effective” IPR protection or “fair and equitable market access to United States persons that rely upon IPR”.

There is apprehension that the USTR might put India on the Priority Foreign Country list for IPR; this names countries judged to have inadequate intellectual property laws or deny fair and equitable market access to US entities relying on IPR protection.
3350384373314e4e53664d414168502f

Such countries may be subject to sanctions. As a part of such penal action, the US may withdraw benefits under the scheme of Generalised System of Preferences, which provides reduced tariffs for Indian goods entering US markets.

The US International Trade Commission, a quasi-judicial independent federal body which advises the US President, the USTR and the nation’s legislature on trade matters, had begun a probe into India’s trade and industrial policies on February 12.

Since US President Barack Obama’s 2010 India visit, American firms, especially a certain segment of the US pharmaceutical industry, have become extremely vocal about Indian policies on domestic content requirements and IPR.

Policy circles here believe the US is doing these to protect the interest of a handful of pharmaceutical companies, which command influence in policy making circles there. These include Pfizer, Bayer and and Swiss pharma major Novartis.

The department of industrial policy and promotion, under the commerce & industry ministry, has prepared a list of all cases since 1974 where the US is held to have breached IPR laws, rejected patents and invoked compulsory licensing, in sectors ranging from electronics to pharmaceuticals.

During the 2002-2012 period, 20 cases related to pharmaceuticals were invalidated by the US Federal District Courts, compared with 34 related to mechanical devices and 10 to medical devices. Between 2007 and 2011, about 280 cases were identified in the US Federal District Courts where patent validity was determined. Of these, the patent was held valid and enforceable in only 39 cases. In 253 cases, the patent was held invalid.

Refusing to deal with the matter bilaterally, the government has apparently told its American counterpart that such issues should be discussed only at multilateral platforms like the World Intellectual Property Organization and WTO. However, following the Novartis and Bayer-Onyx cases here, the US is concerned that other countries such as Brazil, China and in Africa might follow India’s model of compulsory licensing.

IPR war

* Officials decided India will not cooperate with the US on any sort of investigation on Indian IPR or trade laws

* But it will keep the door open for discussion to allay US perceptions on New Delhi's trade laws

* The government is compiling cases where the US had breached IPR laws

* The office of the US Trade Representative is expected to come out with a report on Special 301 by April-end or early May

* Apprehensions that USTR might put India on the Priority Foreign Country list for IPR, making it subject to sanctions
Muahahaha...Let the game begin :devil: Let's show these yanks that how victory is achieved legally without using weapons:butcher:
 
.
our laws are fully compliant with the agreement of the WTO.
India has never deviated..never diluted it.
India follows"due process” before issuing the compulsory license unlike the U.S...which has issued such licenses through executive authority several times.
Under the Indian Patents Act if the government considers a drug to be unaffordable by the nation's general population,it can issue a CL (compulsory license) and grant permission to companies to manufacture a generic version at a fraction of the cost of the original drug.
And according to norms set by the WTO....if it is in the public interest such a license can be awarded by a national government without the consent of the patent owner.
So lets drag US to WTO.:coffee:
 
.
The funny thing is where was the US and the world when yoga forms and techniques as well as Ayrudeva knowledge from our anicent books were being patented in outside of INDIA? Hare Krishna is multi billion orgnaization because it was able to patent our historical knowledge. The trust that runs this group mostly consists of white ppl. NO INDIANS.

Where is the US and the world when CHINA COPIES EVERYTHING FROM THEM? Where are sanctions? I only know of weapons related sanctions....
 
.
some businessmen in US want all these things and they are pressurizing the US govt. most probably because they want to sell the medical drug at similar price or at US export price to earn profit.
 
.
our laws are fully compliant with the agreement of the WTO.
India has never deviated..never diluted it.
India follows"due process” before issuing the compulsory license unlike the U.S...which has issued such licenses through executive authority several times.
Under the Indian Patents Act if the government considers a drug to be unaffordable by the nation's general population,it can issue a CL (compulsory license) and grant permission to companies to manufacture a generic version at a fraction of the cost of the original drug.
And according to norms set by the WTO....if it is in the public interest such a license can be awarded by a national government without the consent of the patent owner.
So lets drag US to WTO.:coffee:
Are you one 100% sure of Indian compliance? If US has no case, why would they make a big stink about it?
 
. .
Are you one 100% sure of Indian compliance? If US has no case, why would they make a big stink about it?
Because US is always sure of their high handedness and this is their pathetic way of threatening developing countries.
Also US is trying to bring down the hammer on countries which supported Russia (on the crimea issue).And thats one reason this decision was taken in haste.
 
.
our laws are fully compliant with the agreement of the WTO.
India has never deviated..never diluted it.
India follows"due process” before issuing the compulsory license unlike the U.S...which has issued such licenses through executive authority several times.
Under the Indian Patents Act if the government considers a drug to be unaffordable by the nation's general population,it can issue a CL (compulsory license) and grant permission to companies to manufacture a generic version at a fraction of the cost of the original drug.
And according to norms set by the WTO....if it is in the public interest such a license can be awarded by a national government without the consent of the patent owner.
So lets drag US to WTO.:coffee:
Are you one 100% sure of Indian compliance? If US has no case, why would they make a big stink about it?



Nah I pretty sure India is not following compliance on certain things. But what about the double standards with regard to CHina?
 
.
Americans say they want developing countries to develop. :lol:

Yet when we produce goods that they consume, they scream their heads off about "our" pollution, when they are outsourcing their own pollution to us, since we are the ones producing them in our factories. It's their pollution, for their goods.

Americans say they want developing countries to invest more in renewable energy.

Yet when India starts producing solar panels, Americans scream and cry again. :lol:

U.S. Tries To Stop India's Solar Policy While Pushing Fight Against Climate Change - Huffington Post

I don't know how America has time to sanction India though, they are already sanctioning half the world over this or that, Russia being their main target for now.
 
Last edited:
.
WTO policy itself stipulates that for life saving drugs, compliance patents can be issued to generic manufacturers ! The current drug in question is precisely that .. As for other drugs, well our laws are for the protection of common man and our courts haven't gone totally insane to value quarterly earnings of a company over in-numerous lives.

So we will NOT allow any ever greening of product ! PERIOD !

Our courts won't be a bitch to multinationals ! PERIOD !
 
.
Nah I pretty sure India is not following compliance on certain things. But what about the double standards with regard to CHina?
US too has defaulted.I've already mentioned as to how US has issued CLs through executive authority several times which is against the norms.
India may not be following all of the norms but atleast it is following "most of" the norms.
 
. .
only thing is Indian business magnets should buy all those pharmaceutical companies in US. Of course they can, but the point is, would they sell?
 
.
Damn fine read!


You truly have to applaud India's stand on these issues. Many Indians try to malign their own government and make out they are incompetent across the board and this instance just goes to highlight this fallacy.

India is not bowing to the US' bullying and is showing the developing world how it's done.
 
.
Back
Top Bottom